Depression is a chronic brain dysfunctional disease mainly due tomood disorders.Currently,the pathogenesis of depression is unclear,and its pathogenesis,pathophysiology and treatment have consistently been a major focus of academic research.This review provides an overview of the role of serum inflammatory factors in the pathogenesis,diagnosis,and treatment of depression.The inflammatory factor pathway provides a theoretical basis for the development of diagnostic and therapeutic methods for depression.It is expected to provide accurate personalized treatment for patients with depression through the treatment of inflammatory factors,improve the treatment outcomest,and reduce the risk of disease progression.

Depression is a chronic brain dysfunctional disease mainly due tomood disorders.Currently,the pathogenesis of depression is unclear,and its pathogenesis,pathophysiology and treatment have consistently been a major focus of academic research.This review provides an overview of the role of serum inflammatory factors in the pathogenesis,diagnosis,and treatment of depression.The inflammatory factor pathway provides a theoretical basis for the development of diagnostic and therapeutic methods for depression.It is expected to provide accurate personalized treatment for patients with depression through the treatment of inflammatory factors,improve the treatment outcomest,and reduce the risk of disease progression.

Tofacitinib is a novel targeted drug for the treatment of rheumatoid arthritis. With the entry into the medical insurance catalogue, the drug will usher in a new era. This paper reviews the effectiveness and safety of tofacitinib in the treatment of rheumatoid arthritis. Generally speaking, tofacitinib has definite efficacy, few adverse reactions, and controllable safety. Tofacitinib has an advantage over biological agents, that is, tofacitinib can be orally administered. Therefore, tofacitinib is especially developed for patients who have a poor response to or who are intolerant to disease-modifying antirheumatic drugs and biological agents. However, the effectiveness and safety of tofacitinib in a Chinese population need to be confirmed by more studies.

Objective:To evaluate the efficacy, safety and economy of recombinant human growth hormone (rhGH) in the treatment of patients with liver cirrhosis and hypoproteinemia.Methods:Computer search for randomized controlled trials included in Chinese Biomedical Literature Database(CBM), Wanfang Medicine, Weipu Medicine, Embase, PubMed, Cochrane Library and other databases from January 1, 2000 to January 1, 2019, and excluded according to certain criteria.RevMan5.3 software was used for statistical analysis.Results:A total of 13 articles were included in the meta-analysis, a total of 739 patients.The results showed that the short-term efficacy of rhGH in the treatment of cirrhosis with hypoproteinemia had no statistically significant difference compared with human serum albumin (HSA)[WMD=-0.42, 95% CI(-1.77, 0.92), P=0.54], but the mid-and long-term effects of rhGH were better[WMD=3.42, 95% CI(0.13, 6.70), P=0.04; WMD=7.12, 95% CI(4.75, 9.50), P<0.001]. Conclusion:The application of rhGH in the treatment of cirrhosis with hypoproteinemia is equivalent to the infusion of HSA in short-term efficacy, but the duration of treatment is prolonged, has no obvious adverse reactions, and is more economical.

A 4 years and 7 months old boy was treated with IV infusions of azithromycin 0.16 g once daily and methylprednisolone sodium succinate 32 mg once daily and oral amoxicillin and clavulanate potassium for suspension 228.5 mg twice daily for bronchopneumonia complicated with multiple co-infections with mycoplasma, viruses, and bacteria. After 6 days of treatments, the boy′s symptoms were improved and his body temperature returned to normal. On the 7th day of treatments, the boy developed rash with itching, which subsided on the same day after symptomatic treatments. Amoxicillin and clavulanate potassium and azithromycin were discontinued, but the child still developed rash every time after IV infusion of methylprednisolone sodium succinate, which could subside later that day. After withdrawal of methylprednisolone sodium succinate, the boy′s rash did not recur.

A 4 years and 7 months old boy was treated with IV infusions of azithromycin 0.16 g once daily and methylprednisolone sodium succinate 32 mg once daily and oral amoxicillin and clavulanate potassium for suspension 228.5 mg twice daily for bronchopneumonia complicated with multiple co-infections with mycoplasma, viruses, and bacteria. After 6 days of treatments, the boy′s symptoms were improved and his body temperature returned to normal. On the 7th day of treatments, the boy developed rash with itching, which subsided on the same day after symptomatic treatments. Amoxicillin and clavulanate potassium and azithromycin were discontinued, but the child still developed rash every time after IV infusion of methylprednisolone sodium succinate, which could subside later that day. After withdrawal of methylprednisolone sodium succinate, the boy′s rash did not recur.

A 62-year-old female patient with left knee osteoarthritis was treated with an IV infusion of compound ossotide injection 90 mg dissolving in 0. 9％ sodium chloride injection 250 ml once a day. About 5 minutes after IV infusion on the first day,the patient complained of chest tightness,dyspnea,cold sweat,upper eyelid edema,cyanosis,and vomiting of pale yellow stomach contents. Her blood pressure was 101 / 72 mmHg,heart rate was 103 beats per minute,breathing rate was 25 times per minute. Compound ossotide injection was discontinued immediately. She was given an intravenous injection of dexamethasone 5 mg and an intramuscular injection of adrenaline 1 mg. About 20 minutes later,her blood pressure decreased to 39 / 24 mmHg,pulse rate was 59 beats per minute,breathing rate was 24 times per minute. She developed urinary and fecal incontinence and drowsiness. The patient was diagnosed as anaphylactic shock caused by compound ossotide injection. She was given an intramuscular injection of adrenaline 1 mg again, an IV infusion of dopamine 160 mg,and symptomatic treatment. About 40 minutes later,her heart rate was 70 beats per minute,blood pressure was 95 / 56 mmHg,breathing rate was 12 times per minute. The patient sequentially received an IV infusion of methylprednisolone 40 mg and an intravenous injection of dopamine 10 mg. About 20 minutes later,the patient regained consciousness. Methylepinephrine 10 mg and dopamine 180 mg were pumped with gradually reduced speed. Twelve hours later,the patient′s symptoms disappeared. Her body temperature was 36. 4 ℃,heart rate was 54 beats per minute,breathing rate was 19 times per minute,and blood pressure was 94 / 57 mmHg.

A 62-year-old female patient with left knee osteoarthritis was treated with an IV infusion of compound ossotide injection 90 mg dissolving in 0. 9％ sodium chloride injection 250 ml once a day. About 5 minutes after IV infusion on the first day,the patient complained of chest tightness,dyspnea,cold sweat,upper eyelid edema,cyanosis,and vomiting of pale yellow stomach contents. Her blood pressure was 101 / 72 mmHg,heart rate was 103 beats per minute,breathing rate was 25 times per minute. Compound ossotide injection was discontinued immediately. She was given an intravenous injection of dexamethasone 5 mg and an intramuscular injection of adrenaline 1 mg. About 20 minutes later,her blood pressure decreased to 39 / 24 mmHg,pulse rate was 59 beats per minute,breathing rate was 24 times per minute. She developed urinary and fecal incontinence and drowsiness. The patient was diagnosed as anaphylactic shock caused by compound ossotide injection. She was given an intramuscular injection of adrenaline 1 mg again, an IV infusion of dopamine 160 mg,and symptomatic treatment. About 40 minutes later,her heart rate was 70 beats per minute,blood pressure was 95 / 56 mmHg,breathing rate was 12 times per minute. The patient sequentially received an IV infusion of methylprednisolone 40 mg and an intravenous injection of dopamine 10 mg. About 20 minutes later,the patient regained consciousness. Methylepinephrine 10 mg and dopamine 180 mg were pumped with gradually reduced speed. Twelve hours later,the patient′s symptoms disappeared. Her body temperature was 36. 4 ℃,heart rate was 54 beats per minute,breathing rate was 19 times per minute,and blood pressure was 94 / 57 mmHg.

Objective To investigate the clinical features and occurrence regularity of drug induced liver injury,so as to provide reference for clinical medication.Methods The choice of hospital 2012 -2014 reported adverse drug reaction monitoring center data,including DILI 30 cases,DILI related data to classify statistics,compre-hensive analysis.Results DILI was of many influence factors,the time of occurrence of large differences,partial onset occult,and related to a drug to immune enhancement agent most(23.33%),followed by anti -tumor drugs (20.00%)and lipid regulating agent(16.67%).Conclusion The medical staff should enhance the understanding of DILI medicine source disease,strengthen the monitoring of adverse drug reactions,as far as possible to reduce the occurrence of DILI,and make its harm to a minimum,reduce the patients pain and medical expenses of disease.

An 88-year-old male patient with chronic obstructive pulmonary disease received an Ⅳ infusion of piperacillin sodium and tazobactam sodium 4.5 g twice daily for lung infection.His renal function was normal before drug use.On day 2,his serum urea and creatinine were 9.7 mmol/L and 164 μmol/L respectively,and 24 hour urine volume was 100 ml.He was given bladder irrigation but still had anuria.Acute renal insufficiency was considered.On day 3,the patient was treated with continuous renal replacement and piperacillin sodium and tazobactam sodium was stopped.On day 6,the urine volume increased to 2 150 ml.After an interval of 4 days,the patient received piperacillin sodium and tazobactam sodium (the same dosage as before) again for secondary lung infection.On the second day,the patient developed oliguria again and his serum urea and creatinine were 34.9 mmol/L and 382 μmol/L respectively.Piperacillin sodium and tazobactam sodium was withdrawn.Two days later,the urine volume increased obviously.Four days later,his serum urea and creatinine were 12.9 mmol/L and 168 μ mol/L respectively.